前列腺癌遗传易感风险评分可能修饰其与2型糖尿病的关联:MCC-Spain研究
基于西班牙MCC-Spain病例对照研究(1047例前列腺癌病例和1379例对照),构建前列腺癌多基因风险评分(PRS)作为遗传易感性代理指标,评估2型糖尿病(T2DM)与前列腺癌的关联是否受肿瘤侵袭性或遗传易感性修饰。结果显示T2DM与总体前列腺癌的负关联仅限于ISUP 1级肿瘤(OR=0.72,95%CI 0.53-0.98),且T2DM与前列腺癌风险随糖尿病治疗时长变化(二甲双胍负相关、胰岛素正相关),低PRS者中T2DM与更低前列腺癌风险强关联(OR tertile 1=0.31,95%CI 0.11-0.87)。
要点
- T2DM与前列腺癌负关联仅见于ISUP 1级肿瘤,可能反映检测偏倚
- T2DM与前列腺癌风险随治疗时长变化:二甲双胍负相关、胰岛素正相关
- 低PRS者中T2DM与前列腺癌风险降低强关联(OR=0.31),独立于ISUP分级
核心结论
- T2DM与前列腺癌的负关联可能受肿瘤侵袭性和个体遗传易感性修饰,研究两者关系时需纳入侵袭性、易感性和T2DM治疗。
研究设计与样本
- 基于西班牙7个省的MCC-Spain人群病例对照研究,纳入1047例 incident 前列腺癌病例和1379例随机选择的对照。
- 肿瘤按ISUP分级分类侵袭性,构建前列腺癌多基因风险评分(PRS)作为遗传易感性代理,采用混合 logistic 回归和多分类 logistic 回归分析,并纳入PRS交互项及按PRS三分位分层分析。
主要发现
- T2DM与总体前列腺癌的负关联仅限于ISUP 1级肿瘤(OR=0.72,95%CI 0.53-0.98)。
- 前列腺癌风险随糖尿病治疗时长变化:与二甲双胍负相关、与胰岛素正相关,且无侵袭性差异。
- 低PRS者中T2DM与更低前列腺癌风险强关联(OR tertile 1=0.31,95%CI 0.11-0.87),独立于ISUP分级。
关键数值与推荐
- ISUP 1级肿瘤中T2DM与前列腺癌的OR=0.72(95%CI 0.53-0.98)。
- PRS最低三分位组中T2DM与前列腺癌的OR=0.31(95%CI 0.11-0.87)。
临床怎么用
- 评估T2DM与前列腺癌风险关系时应考虑肿瘤ISUP分级和患者遗传易感性(PRS)。
- 关注T2DM治疗药物(二甲双胍、胰岛素)对前列腺癌风险关联的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some studies have reported an inverse association between type 2 diabetes mellitus (T2DM) and prostate cancer (PCa), but results on this issue are still inconsistent. In this study, we evaluate whether this heterogeneity might be related to differences in this relationship by tumour or by individual genetic susceptibility to PCa. METHODS: We studied 1047 incident PCa cases and 1379 randomly selected controls, recruited in 7 Spanish provinces for the population-based MCC-Spain case-control. Tumour were classified by aggressiveness according to the International Society of Urological Pathology (ISUP), and we constructed a PCa polygenic risk score (PRS) as proxy for genetic susceptibility. The epidemiological questionnaire collected detailed self-reported data on T2DM diagnosis and treatment. The association between T2DM status and PCa was studied by fitting mixed logistic regression models, and, for its association by aggressiveness of PCa, with multinomial logistic regression models. To evaluate the possible modulator role of PRS in this relationship, we included the corresponding interaction term in the model, and repeated the analysis stratified by PRS tertiles. RESULTS: Globally, our results showed an inverse association between T2DM and overall PCa limited to grade 1 tumours (ORISUP = 1: 0.72; 95% CI: 0.53-0.98), which could be compatible with a detection bias. However, PCa risk also varied with duration of diabetes treatment -inversely to metformin and positively with insulin-, without differences by aggressiveness. When we considered genetic susceptibility, T2DM was more strongly associated with lower PCa risk in those with lower PRS (ORtertile 1: 0.31; 95% CI: 0.11-0.87), independently of ISUP grade. CONCLUSIONS: Our findings reinforce the need to include aggressiveness and susceptibility of PCa, and T2DM treatments in the study of the relationship between both diseases.
引用
- Barrios-Rodríguez R, García-Esquinas E, Pérez-Gómez B, et al. Prostate cancer genetic propensity risk score may modify the association between this tumour and type 2 diabetes mellitus (MCC-Spain study). Prostate Cancer Prostatic Dis. 2021. PMID: 34601492. doi:10.1038/s41391-021-00446-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。